Investigating how entinostat and neoantigen vaccination can improve treatment for bladder cancer
Official title: Effects of entinostat and neoantigen vaccination on bladder cancer
Funded at Univ of North Carolina Chapel Hill · NIH-10913372 · Data updated 2026-11-12
This study is looking at a new way to help people with advanced bladder cancer by combining a special treatment called entinostat with a vaccine that targets cancer, to see if it can boost the immune system's ability to fight the disease, especially for those who haven't had success with other therapies.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $53,974 |
| NIH project number | 5F30CA278317-02 |
| Project ID | NIH-10913372 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with advanced bladder cancer who have not responded adequately to current immune checkpoint therapies.
✕Less likely to help
Patients with early-stage bladder cancer or those who have not been diagnosed with bladder cancer may not receive any benefit from this research.
What this research studies
This research focuses on improving treatment outcomes for patients with advanced bladder cancer by exploring the effects of entinostat, a histone deacetylase inhibitor, combined with neoantigen vaccination. The study aims to understand how this combination can enhance the immune response against bladder cancer, particularly in patients who do not respond well to existing immune checkpoint blockade therapies. By examining the mechanisms behind these treatments in a mouse model, researchers hope to identify which patients are most likely to benefit and how to optimize their responses. The ultimate goal is to develop a more effective treatment strategy for bladder cancer patients.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and better survival rates for patients with advanced bladder cancer.
How similar studies have gone: Previous research has shown promising results with similar approaches in enhancing immune responses in cancer treatment, indicating potential for success in this study.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Beckabir, Wolfgang — Univ of North Carolina Chapel Hill
- Study coordinator: Beckabir, Wolfgang
Related research
Other NIH-funded projects on the same topics.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Respiratory pathogen–specific T cell signatures after vaccination, infection, and treatment
A research effort to map how immune T cells respond to respiratory infections and vaccines, with potential to guide better vaccines and treatments for conditions like covid-19 and pertussis.
-
Malaria vaccine and infection: how the body’s early and later immune responses relate to protection
Researchers are studying how people’s immune systems respond to the malaria pre-erythrocytic stage, whether after vaccination or infection, to identify which responses are linked to protection.
-
Spatially responsive mass vaccination for urban rabies
A new plan uses data and maps to place vaccination sites where they’re most needed in cities, aiming to boost rabies vaccination for both people and dogs.
-
Spatially responsive mass vaccination for urban rabies
A project tests smarter placement of vaccination sites to increase mass canine rabies vaccination in cities.
-
Vaccine failure after Covid-19 vaccination in older adults
This project follows vaccinated older adults to understand who among them still gets Covid-19 and what factors make those outcomes worse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.